Chandrashekar R Giliyar

20050096365, May 5, 2005

Nov 3, 2003

10/700838

David Fikstad - Salt Lake City UT, US
Srinivasan Venkateshwaran - Salt Lake City UT, US
Chandrashekar Giliyar - Salt Lake City UT, US
Mahesh Patel - Salt Lake City UT, US

A61K031/724
A61K031/426
A61K031/355

514369000, 514423000, 514469000, 514458000, 514058000

Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.

20060003002, Jan 5, 2006

May 4, 2005

11/122788

David Fikstad - Salt Lake City UT, US
Srinivasan Venkateshwaran - Salt Lake City UT, US
Chandrashekar Giliyar - Salt Lake City UT, US
Mahesh Patel - Salt Lake City UT, US

A61K 31/724
A61K 31/401
A61K 31/366
A61K 9/22
A61K 31/355
A61K 31/225

424468000, 514423000, 514460000, 514458000, 514058000, 514548000

Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.

20070281927, Dec 6, 2007

Jun 6, 2006

11/448597

Shanthakumar Tyavanagimatt - Salt Lake City UT, US
David Fikstad - Salt Lake City UT, US
Chandrashekar Giliyar - Salt Lake City UT, US
Mahesh Patel - Salt Lake City UT, US
Srinivasan Venkateshwaran - Salt Lake City UT, US

A61K 31/5415

5142265

Methods and compositions for delivering a meloxicam compound are disclosed and described. In one aspect, a method may include perorally administering to a subject a therapeutically effective amount of a meloxicam compound that provides a meloxicam plasma concentration within 1 hour which is at least about 40% of the maximum plasma concentration attained by the formulation. In another aspect, a composition may include a therapeutically effective amount of a meloxicam compound in a pharmaceutically acceptable carrier including at least one of an alkalizer or a solubilizer, with the meloxicam compound having a solubility in the carrier that is greater than about 1.0 mg/gm.

20100136105, Jun 3, 2010

Nov 24, 2009

12/625309

MAHESH V. PATEL - SALT LAKE CITY UT, US
DAVID T. FIKSTAD - STANFORD CA, US
HUIPING ZHANG - MALVERN PA, US
CHANDRASHEKAR GILIYAR - SALT LAKE CITY UT, US

LIPOCINE, INC. - Salt Lake City UT

A61K 38/22
A61K 9/10
A61P 5/24
A61K 9/66
A61K 9/20

424455, 514 12, 424489, 424464, 977773, 977904

The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.

20100137271, Jun 3, 2010

Nov 24, 2009

12/625284

MAHESH V. PATEL - SALT LAKE CITY UT, US
DAVID T. FIKSTAD - STANFORD CA, US
HUIPING ZHANG - MALVERN PA, US
CHANDRASHEKAR GILIYAR - SALT LAKE CITY UT, US

LIPOCINE, INC. - Salt Lake City UT

A61K 31/569
A61K 31/57
A61K 31/568
A61P 5/24
A61P 5/30

514181, 514177, 514178

Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.

20100173882, Jul 8, 2010

Jan 8, 2009

12/350930

Chandrashekar Giliyar - Salt Lake City UT, US
Nachiappan Chidambaram - Sandy UT, US
Mahesh V. Patel - Salt Lake City UT, US
Srinivasan Venkateshwaran - Salt Lake City UT, US

LIPOCINE, INC. - Salt Lake City UT

A61K 31/568
A61P 5/26

514178

Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

20110312927, Dec 22, 2011

Jun 18, 2010

12/819125

Satish Kumar Nachaegari - Salt Lake City UT, US
Chandrashekar Giliyar - Salt Lake City UT, US
Chidambaram Nachiappan - Sandy UT, US
Linus Fonkwe - West Valley City UT, US
Mahesh Patel - Salt Lake City UT, US
Srinivasan Venkateshwaran - Salt Lake City UT, US

A61K 31/57
A61P 15/00
A61P 15/08

514177

The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10hr/mL:1

20110312928, Dec 22, 2011

Aug 5, 2011

13/204562

Satish Kumar Nachaegari - Salt Lake City UT, US
Chandrashekar Giliyar - Salt Lake City UT, US
Chidambaram Nachiappan - Sandy UT, US
Mahesh V. Patel - Salt Lake City UT, US
Srinivasan Venkateshwaran - Salt Lake City UT, US

Lipocine Inc. - Salt Lake City UT

A61K 31/57
A61P 15/00
A61P 15/18
A61P 15/16
A61P 35/00
A61P 19/10

514177

The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10−6 hr/mL:1.